The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Vaccines for measles, mumps, rubella, and varicella in children
Open accessAbstract
BACKGROUND: Measles, mumps, rubella, and varicella (chickenpox) are serious diseases that can lead to serious complications, disability, and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness. This is an update of a review published in 2005 and updated in 2012. OBJECTIVES: To assess the effectiveness, safety, and long- and short-term adverse effects associated with the trivalent vaccine, containing measles, rubella, mumps strains (MMR), or concurrent administration of MMR vaccine and varicella vaccine (MMR+V), or tetravalent vaccine containing measles, rubella, mumps, and varicella strains (MMRV), given to children aged up to 15 years. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2019, Issue 5), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to 2 May 2019), Embase (1974 to 2 May 2019), the WHO International Clinical Trials Registry Platform (2 May 2019), and ClinicalTrials.gov (2 May 2019). SELECTION CRITERIA: We included randomised controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective cohort studies (PCS/RCS), case-control studies (CCS), interrupted time-series (ITS) studies, case cross-over (CCO) studies, case-only ecological method (COEM) studies, self-controlled case series (SCCS) studies, person-time cohort (PTC) studies, and case-coverage design/screening methods (CCD/SM) studies, assessing any combined MMR or MMRV / MMR+V vaccine given in any dose, preparation or time schedule compared with no intervention or placebo, on healthy children up to 15 years of age. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed the methodological quality of the included studies. We grouped studies for quantitative analysis according to study design, vaccine type (MMR, MMRV, MMR+V), virus strain, and study settings. Outcomes of interest were cases of measles, mumps, rubella, and varicella, and harms. Certainty of evidence of was rated using GRADE. MAIN RESULTS: We included 138 studies (23,480,668 participants). Fifty-one studies (10,248,159 children) assessed vaccine effectiveness and 87 studies (13,232,509 children) assessed the association between vaccines and a variety of harms. We included 74 new studies to this 2019 version of the review. Effectiveness Vaccine effectiveness in preventing measles was 95% after one dose (relative risk (RR) 0.05, 95% CI 0.02 to 0.13; 7 cohort studies; 12,039 children; moderate certainty evidence) and 96% after two doses (RR 0.04, 95% CI 0.01 to 0.28; 5 cohort studies; 21,604 children; moderate certainty evidence). The effectiveness in preventing cases among household contacts or preventing transmission to others the children were in contact with after one dose was 81% (RR 0.19, 95% CI 0.04 to 0.89; 3 cohort studies; 151 children; low certainty evidence), after two doses 85% (RR 0.15, 95% CI 0.03 to 0.75; 3 cohort studies; 378 children; low certainty evidence), and after three doses was 96% (RR 0.04, 95% CI 0.01 to 0.23; 2 cohort studies; 151 children; low certainty evidence). The effectiveness (at least one dose) in preventing measles after exposure (post-exposure prophylaxis) was 74% (RR 0.26, 95% CI 0.14 to 0.50; 2 cohort studies; 283 children; low certainty evidence). The effectiveness of Jeryl Lynn containing MMR vaccine in preventing mumps was 72% after one dose (RR 0.24, 95% CI 0.08 to 0.76; 6 cohort studies; 9915 children; moderate certainty evidence), 86% after two doses (RR 0.12, 95% CI 0.04 to 0.35; 5 cohort studies; 7792 children; moderate certainty evidence). Effectiveness in preventing cases among household contacts was 74% (RR 0.26, 95% CI 0.13 to 0.49; 3 cohort studies; 1036 children; moderate certainty evidence). Vaccine effectiveness against rubella, using a vaccine with the BRD2 strain which is only used in China, is 89% (RR 0.11, 95% CI 0.03 to 0.42; 1 cohort study; 1621 children; moderate certainty evidence). Vaccine effectiveness against varicella (any severity) after two doses in children aged 11 to 22 months is 95% in a 10 years follow-up (rate ratio (rr) 0.05, 95% CI 0.03 to 0.08; 1 RCT; 2279 children; high certainty evidence). Safety There is evidence supporting an association between aseptic meningitis and MMR vaccines containing Urabe and Leningrad-Zagreb mumps strains, but no evidence supporting this association for MMR vaccines containing Jeryl Lynn mumps strains (rr 1.30, 95% CI 0.66 to 2.56; low certainty evidence). The analyses provide evidence supporting an association between MMR/MMR+V/MMRV vaccines (Jeryl Lynn strain) and febrile seizures. Febrile seizures normally occur in 2% to 4% of healthy children at least once before the age of 5. The attributable risk febrile seizures vaccine-induced is est
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wakefield, A., Murch, S., Anthony, A., Linnell, J., Casson, D., Malik, M., Berelowitz, M., Dhillon, A., Thomson, M., Harvey, P., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11096-0 · Cited by 3,006
RetractedRetraction of an interpretation
Murch, S. H., Anthony, A., Casson, D. H., Malik, M., Berelowitz, M., Dhillon, A. P., Thomson, M. A., Valentine, A., Davies, S. E., & Walker-Smith, J. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15715-2 · Cited by 321
RetractedStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327
The Use and Interpretation of Quasi-Experimental Studies in Medical Informatics
Harris, A. D., McGregor, J. C., Perencevich, E. N., Furuno, J. P., Zhu, J., Peterson, D. E., & Finkelstein, J. (2006) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m1749 · Cited by 1,023
A Twin Study of Autism in Denmark, Finland, Iceland, Norway and Sweden
Steffenburg, S., Gillberg, C., Hellgren, L., Andersson, L., Gillberg, I. C., Jakobsson, G., & Bohman, M. (1989) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.1989.tb00254.x · Cited by 780
Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association
Taylor, B., Miller, E., Farrington, C., Petropoulos, M.-C., Favot-Mayaud, I., Li, J., & Waight, P. A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01239-8 · Cited by 753
Self controlled case series methods: an alternative to standard epidemiological study designs
Petersen, I., Douglas, I., & Whitaker, H. (2016) · BMJ · doi:10.1136/bmj.i4515 · Cited by 525
Fombonne, E., Zakarian, R., Bennett, A., Meng, L., & McLean-Heywood, D. (2006) · Pediatrics · doi:10.1542/peds.2005-2993 · Cited by 399
Vaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub3 · Cited by 372
Self-citationTime trends in autism and in MMR immunization coverage in California
Dales, L. (2001) · JAMA · doi:10.1001/jama.285.9.1183 · Cited by 340
Vaccines and Autism: A Tale of Shifting Hypotheses
Gerber, J. S., & Offit, P. A. (2009) · Clinical Infectious Diseases · doi:10.1086/596476 · Cited by 339
Farrington, P., Rush, M., Miller, E., Pugh, S., Colville, A., Flower, A., Nash, J., & Morgan-Capner, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90471-9 · Cited by 338
No evidence for a new variant of measles-mumps-rubella-induced autism
Fombonne, E., & Chakrabarti, S. (2001) · PEDIATRICS · doi:10.1542/peds.108.4.e58 · Cited by 312
MMR vaccination and pervasive developmental disorders: a case-control study
Smeeth, L., Cook, C., Fombonne, E., Heavey, L., Rodrigues, L. C., Smith, P. G., & Hall, A. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17020-7 · Cited by 263
Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England
Cohen, C., White, J. M., Savage, E. J., Glynn, J. R., Choi, Y., Andrews, N., Brown, D., & Ramsay, M. E. (2007) · Emerging infectious diseases · doi:10.3201/eid1301.060649 · Cited by 241
Neurologic disorders after measles-mumps-rubella vaccination
Mäkelä, A., Nuorti, J. P., & Peltola, H. (2002) · PEDIATRICS · doi:10.1542/peds.110.5.957 · Cited by 183
MMR Vaccination and Febrile Seizures: Evaluation of Susceptible Subgroups and Long-term Prognosis
Vestergaard, M., Hviid, A., Madsen, K. M., Wohlfahrt, J., Thorsen, P., Schendel, D., Melbye, M., & Olsen, J. (2004) · JAMA · doi:10.1001/jama.292.3.351 · Cited by 170
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children
France, E. K., Glanz, J., Xu, S., Hambidge, S., Yamasaki, K., Black, S. B., Marcy, M., Mullooly, J. P., Jackson, L. A., Nordin, J., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1578 · Cited by 165
MMR vaccine and idiopathic thrombocytopaenic purpura
Black, C., Kaye, J. A., & Jick, H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01790.x · Cited by 137
DeStefano, F., Bhasin, T. K., Thompson, W. W., Yeargin-Allsopp, M., & Boyle, C. (2004) · PEDIATRICS · doi:10.1542/peds.113.2.259 · Cited by 135
Mumps vaccine performance among university students during a mumps outbreak
Cortese, M. M., Jordan, H. T., Curns, A. T., Quinlan, P. A., Ens, K. A., Denning, P. M., & Dayan, G. H. (2008) · Clinical Infectious Diseases · doi:10.1086/529141 · Cited by 125
Davis, R. L. (2001) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.155.3.354 · Cited by 123
Outbreak of mumps in a vaccinated child population: a question of vaccine failure?
Vandermeulen, C., Roelants, M., Vermoere, M., Roseeuw, K., Goubau, P., & Hoppenbrouwers, K. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.02.001 · Cited by 122
Vaccination and allergic disease: a birth cohort study
McKeever, T. M., Lewis, S. A., Smith, C., & Hubbard, R. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.6.985 · Cited by 114
Childhood vaccinations and risk of asthma
DESTEFANO, F., GU, D., KRAMARZ, P., TRUMAN, B. I., IADEMARCO, M. F., MULLOOLY, J. P., JACKSON, L. A., DAVIS, R. L., BLACK, S. B., SHINEFIELD, H. R., et al. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200206000-00004 · Cited by 109
Dourado, I., Cunha, S., Teixeira, M. D. G., Farrington, C. P., Melo, A., Lucena, R., & Barreto, M. L. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010239 · Cited by 95
Ray, P., Hayward, J., Michelson, D., Lewis, E., Schwalbe, J., Black, S., Shinefield, H., Marcy, M., Huff, K., Ward, J., et al. (2006) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000234067.84848.e1 · Cited by 91
Marin, M., Nguyen, H. Q., Langidrik, J. R., Edwards, R., Briand, K., Papania, M. J., Seward, J. F., & LeBaron, C. W. (2006) · Clinical Infectious Diseases · doi:10.1086/498902 · Cited by 91
Miller, E., Andrews, N., Stowe, J., Grant, A., Waight, P., & Taylor, B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk045 · Cited by 76
Mrożek-Budzyn, D., Kiełtyka, A., & Majewska, R. (2010) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181c40a8a · Cited by 72
Weibel, R. E., Carlson, A. J., Villarejos, V. M., Buynak, E. B., McLean, A. A., & Hilleman, M. R. (1980) · Experimental Biology and Medicine · doi:10.3181/00379727-165-40979 · Cited by 64
Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine
Benjamin, C. M., Chew, G. C., & Silman, A. J. (1992) · BMJ · doi:10.1136/bmj.304.6834.1075 · Cited by 63
Lerman, S. J., Bollinger, M., & Brunken, J. M. (1981) · PEDIATRICS · doi:10.1542/peds.68.1.18 · Cited by 62
Effectiveness of previous mumps vaccination during a summer camp outbreak
Schaffzin, J. K., Pollock, L., Schulte, C., Henry, K., Dayan, G., Blog, D., & Smith, P. (2007) · PEDIATRICS · doi:10.1542/peds.2006-3451 · Cited by 60
MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan
Uchiyama, T., Kurosawa, M., & Inaba, Y. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0157-3 · Cited by 58
Schlegel, M., Osterwalder, J. J., Galeazzi, R. L., & Vernazza, P. L. (1999) · BMJ · doi:10.1136/bmj.319.7206.352 · Cited by 56
Bertuola, F., Morando, C., Menniti-Ippolito, F., Da Cas, R., Capuano, A., Perilongo, G., & Da Dalt, L. (2010) · Drug Safety · doi:10.2165/11530350-000000000-00000 · Cited by 53
Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population
Ong, G., Goh, K. T., Ma, S., & Chew, S. K. (2005) · Journal of Infection · doi:10.1016/j.jinf.2004.10.001 · Cited by 50
Makino, S. (1990) · American Journal of Diseases of Children · doi:10.1001/archpedi.1990.02150320069030 · Cited by 47
Risk of serious neurologic disease after immunization of young children in Britain and Ireland
Ward, K. N., Bryant, N. J., Andrews, N. J., Bowley, J. S., Ohrling, A., Verity, C. M., Ross, E. M., & Miller, E. (2007) · PEDIATRICS · doi:10.1542/peds.2006-3743 · Cited by 46
Trivalent Combined Measles-Mumps-Rubella Vaccine: Findings in Clinical-Laboratory Studies
Stokes, J. (1971) · JAMA · doi:10.1001/jama.1971.03190140033006 · Cited by 43
Stowe, J., Andrews, N., Taylor, B., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.12.038 · Cited by 43
Measles-mumps-rubella vaccination and asthma-like disease in early childhood
Hviid, A., & Melbye, M. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn253 · Cited by 35
MMR: marginalised, misrepresented and rejected? Autism: a focus group study
Hilton, S., Hunt, K., & Petticrew, M. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.109686 · Cited by 31
Edees, S., Pullan, C. R., & Hull, D. (1991) · Public Health · doi:10.1016/s0033-3506(05)80282-3 · Cited by 30
Clinical Evaluation of a New Measles-Mumps-Rubella Trivalent Vaccine
Schwarz, A. J. F. (1975) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1975.02120490026008 · Cited by 27
No evidence of an association between MMR vaccine and gait disturbance
Miller, E. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2003.048165 · Cited by 26
MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002
Seagroatt, V. (2005) · BMJ · doi:10.1136/bmj.38449.476759.ae · Cited by 21
Park, T., Ki, M., & Yi, S. (2004) · Statistics in Medicine · doi:10.1002/sim.1540 · Cited by 15
Bremner, S. A., Carey, I. M., DeWilde, S., Richards, N., Maier, W. C., Hilton, S. R., Strachan, D. P., & Cook, D. G. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02697.x · Cited by 15
Beyerlein, A., Strobl, A. N., Winkler, C., Carpus, M., Knopff, A., Donnachie, E., Ankerst, D. P., & Ziegler, A.-G. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.02.049 · Cited by 13
Sharma, H. J., Aly Oun, S., Abou Bakr, S. S., Kapre, S. V., Jadhav, S. S., Dhere, R. M., & Bhardwaj, S. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03121.x · Cited by 13
Combined trivalent and bivalent measles, mumps and rubella virus vaccination: A controlled trial
Swartz, T. A., Klingberg, W., & Klingberg, M. A. (1974) · Infection · doi:10.1007/bf01642228 · Cited by 11
Evaluation of a trivalent measles, mumps, rubella vaccine in children
Bloom, J. L., Schiff, G. M., Graubarth, H., Lipp, R. W., Jackson, J. E., Osborn, R. L., & Kenny, M. T. (1975) · The Journal of Pediatrics · doi:10.1016/s0022-3476(75)80076-x · Cited by 10
Metadata
- Authors
- Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2020-04-20
- Volume
- 11
- Pages
- CD004407-CD004407
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W3017107833
- Cited by
- 193
- References
- 56
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.